NHS Blood and Transplant Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2015
NCT03136445
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

NHS Blood and Transplant

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetic Nephropathies (Phase 2)

Hematologic Neoplasms (Phase 3)

Hemorrhage (Phase 3)

Kidney Diseases (Phase 2)

Thrombocytopenia (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 7